In addition, the PIK3CA-mutant tumor might respond well to the selective inhibition of PIK3CA, such as copanlisib or alpelisib, rather than PI3K inhibitors, since the activation event is selective [64]. This evidence concerns the gene PIK3CA and neoplasm.